NUR 210/ NUR210 Exam 1 – Principles of
Pharmacology Review ACTUAL EXAM
2026/2027 | Principles of Pharmacology
Review | Verified Q&A | Pass Guaranteed
- A+ Graded
ART A – MULTIPLE CHOICE (Q1–60)
P
Q1 (Pharmacokinetics – first-pass effect): A patient is prescribed nitroglycerin for acute angina.
The nurse understands that the oral route is avoided for this medication primarily because of
which pharmacokinetic principle?
A. The drug is extensively metabolized by the liver before reaching systemic circulation.
B. The drug is poorly absorbed from the gastrointestinal tract.
C. The drug causes severe gastric irritation when given orally.
D. The drug has a very long half-life and accumulates with oral dosing.
[CORRECT] A
Rationale: The first-pass effect refers to the rapid metabolism of orally administered drugs by
the liver via the portal circulation before they reach systemic circulation, significantly reducing
bioavailability; nitroglycerin has nearly 100% first-pass metabolism, making sublingual or
transdermal routes necessary. Distractor B is incorrect because nitroglycerin is actually well
absorbed from the GI tract but is immediately inactivated by hepatic enzymes. Clinical pearl for
Galen students: Always consider first-pass effect when comparing oral versus parenteral
bioavailability — drugs with high first-pass metabolism require alternative routes to achieve
therapeutic plasma levels.
Q2 (Pharmacokinetics – absorption factors): Which factor would most likely DECREASE the
rate of absorption of an orally administered medication?
A. Taking the medication with a high-fat meal
B. Administering the medication on an empty stomach
C. Using a liquid formulation instead of a tablet
D. Increasing gastric pH with an antacid
[CORRECT] A
Rationale: High-fat meals delay gastric emptying and can reduce the rate of drug absorption by
slowing transit to the small intestine, where most absorption occurs; fats may also bind certain
lipophilic drugs, further reducing availability. Distractor D is incorrect because increasing gastric
pH with antacids can actually enhance absorption of acid-labile drugs by protecting them from
degradation in the stomach. Clinical pearl for Galen students: Always check whether a
medication should be taken with food or on an empty stomach — food can either enhance,
delay, or have no effect on absorption depending on the drug's physicochemical properties.
, 3 (Pharmacokinetics – protein binding): A patient with severe liver cirrhosis has low serum
Q
albumin levels. The nurse anticipates that administration of warfarin, a highly protein-bound
drug, will result in which effect?
A. Decreased therapeutic effect due to increased protein binding
B. Increased risk of bleeding due to higher free drug concentration
C. Prolonged half-life due to decreased hepatic metabolism
D. Decreased drug distribution to target tissues
[CORRECT] B
Rationale: When albumin levels are low, fewer protein-binding sites are available, resulting in a
higher proportion of free (unbound) warfarin circulating in the plasma; free drug is
pharmacologically active and can cause enhanced anticoagulant effects and bleeding risk.
Distractor A is incorrect because decreased albumin actually reduces protein binding, not
increases it. Clinical pearl for Galen students: In patients with hypoalbuminemia (liver disease,
malnutrition, nephrotic syndrome), monitor closely for toxicity with highly protein-bound drugs
like warfarin, furosemide, and phenytoin — free drug levels increase even when total drug levels
appear normal.
Q4 (Pharmacokinetics – blood-brain barrier): The nurse is caring for a patient receiving
morphine for postoperative pain. Which statement best explains why morphine can cross the
blood-brain barrier while many other drugs cannot?
A. Morphine is highly ionized at physiological pH, facilitating passive diffusion.
B. Morphine is lipophilic enough to penetrate the lipid bilayer of the blood-brain barrier.
C. Morphine uses active transport carriers specific to opioid peptides.
D. Morphine is a small molecule that passes through fenestrations in capillary walls.
[CORRECT] B
Rationale: The blood-brain barrier consists of tight junctions between capillary endothelial cells
with a lipid bilayer membrane; lipophilic (lipid-soluble) drugs like morphine can diffuse across
this barrier, whereas hydrophilic (water-soluble) drugs are generally excluded. Distractor A is
incorrect because ionized drugs are typically water-soluble and cannot cross lipid membranes
easily — it is the non-ionized form that crosses. Clinical pearl for Galen students: Lipophilicity is
the key determinant of blood-brain barrier penetration; benzodiazepines, opioids, and general
anesthetics cross easily, while most antibiotics and polar drugs require special transport
mechanisms or inflamed meninges to enter the CNS.
Q5 (Pharmacokinetics – half-life): A drug has a half-life of 6 hours. Approximately how long will
it take for the drug to reach steady-state concentration with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
[CORRECT] D
Rationale: Steady-state concentration is typically reached after approximately 4 to 5 half-lives of
a drug; with a 6-hour half-life, this equates to 24–30 hours (5 × 6 = 30 hours), at which point
drug elimination equals drug administration and plasma levels plateau. Distractor C (24 hours =
4 half-lives) represents near-steady state but not full steady state. Clinical pearl for Galen
students: Use the "5 half-lives rule" to estimate when to expect therapeutic effects or when to
, raw trough levels — for drugs with long half-lives (e.g., digoxin ~36 hours), loading doses may
d
be needed to achieve therapeutic levels quickly.
Q6 (Pharmacokinetics – renal elimination): A patient with chronic kidney disease (CrCl 25
mL/min) is prescribed gentamicin. The nurse knows that renal impairment will primarily affect
which pharmacokinetic parameter?
A. Absorption from the GI tract
B. Volume of distribution
C. Elimination half-life
D. First-pass metabolism
[CORRECT] C
Rationale: The kidneys are the primary route of elimination for aminoglycosides like gentamicin;
impaired renal function decreases glomerular filtration rate (GFR), leading to reduced drug
clearance, accumulation of the drug, and a prolonged elimination half-life. Distractor D is
incorrect because first-pass metabolism is a hepatic process, not renal. Clinical pearl for Galen
students: For renally eliminated drugs (aminoglycosides, vancomycin, digoxin, lithium), always
check creatinine clearance before dosing and adjust intervals or doses accordingly —
therapeutic drug monitoring (TDM) is essential for narrow therapeutic index drugs.
Q7 (Pharmacokinetics – placental transfer): A pregnant patient at 28 weeks gestation asks the
nurse whether the antibiotic she is taking will harm her baby. The nurse's best response is
based on which principle?
A. All drugs cross the placenta and cause teratogenic effects.
B. Only lipid-soluble, non-ionized, low-molecular-weight drugs readily cross the placenta.
C. The placenta is an absolute barrier that prevents all drug transfer to the fetus.
D. Only drugs with a molecular weight greater than 1000 Daltons can cross the placenta.
[CORRECT] B
Rationale: The placenta allows passive diffusion of lipid-soluble, non-ionized,
low-molecular-weight drugs; water-soluble, ionized, and high-molecular-weight drugs (like
heparin) do not readily cross, making this the most accurate explanation for drug transfer risk
assessment. Distractor A is incorrect because not all drugs cross the placenta, and not all that
cross are teratogenic. Clinical pearl for Galen students: When counseling pregnant patients,
remember the PLLR (Pregnancy and Lactation Labeling Rule) — the old A/B/C/D/X categories
were replaced in 2015 with narrative summaries; always consult LactMed for lactation safety
and the PLLR for pregnancy risk information.
Q8 (Pharmacokinetics – CYP450 metabolism): A patient taking warfarin is started on
fluconazole for a fungal infection. The nurse monitors for signs of bleeding because fluconazole
inhibits which enzyme system?
A. Cytochrome P450 3A4
B. Cytochrome P450 2D6
C. Cytochrome P450 2C9
D. Cytochrome P450 1A2
[CORRECT] C
Rationale: Warfarin is primarily metabolized by CYP2C9; fluconazole is a potent inhibitor of
CYP2C9 and CYP3A4, reducing warfarin metabolism and increasing its plasma concentration,
which elevates INR and bleeding risk. Distractor A is incorrect because while CYP3A4 is also
, inhibited by fluconazole, warfarin's S-enantiomer (more potent) is specifically metabolized by
CYP2C9. Clinical pearl for Galen students: Memorize major CYP450 interactions — CYP3A4
(metabolizes ~50% of drugs), CYP2D6 (many antidepressants, beta-blockers), CYP2C9
(warfarin, NSAIDs), and CYP1A2 (theophylline, caffeine); inhibitors increase drug levels,
inducers decrease them.
Q9 (Pharmacokinetics – loading dose): A patient with atrial fibrillation is started on digoxin. The
physician orders a loading dose followed by a maintenance dose. The nurse understands that a
loading dose is given to:
A. Reduce the risk of adverse effects during initial therapy.
B. Achieve therapeutic plasma concentration more rapidly.
C. Compensate for poor oral bioavailability of the drug.
D. Prevent drug accumulation in patients with renal impairment.
[CORRECT] B
Rationale: A loading dose is a higher initial dose administered to rapidly achieve therapeutic
plasma drug concentrations; without it, drugs with long half-lives (like digoxin, ~36 hours) would
take many days to reach steady state at maintenance dosing alone. Distractor A is incorrect
because loading doses actually increase the risk of adverse effects due to higher initial plasma
levels. Clinical pearl for Galen students: Loading doses are commonly used for antibiotics
(vancomycin), antiarrhythmics (amiodarone, digoxin), and anticoagulants — always verify the
patient's renal and hepatic function before administering, as impaired clearance increases
toxicity risk.
Q10 (Pharmacokinetics – steady state): A nurse is teaching a patient about a new
antihypertensive medication with a half-life of 12 hours. The patient asks when they can expect
the full blood pressure-lowering effect. The nurse's best response is:
A. "You should see the full effect within 2 to 3 days."
B. "The full effect will occur after about 5 to 6 days."
C. "The medication works immediately after the first dose."
D. "It may take up to 2 weeks for the full effect."
[CORRECT] B
Rationale: With a 12-hour half-life, steady-state concentration is reached in approximately 4 to 5
half-lives (48–60 hours, or 2 to 2.5 days); however, the full clinical effect of antihypertensives
may take slightly longer as vascular remodeling occurs, making 5 to 6 days a reasonable clinical
estimate. Distractor A underestimates the time needed, and D overestimates it for this half-life.
Clinical pearl for Galen students: When counseling patients on new medications, explain that
steady state is a pharmacokinetic concept (4–5 half-lives), but clinical effects may take
additional time — never discontinue antihypertensives before steady state is reached unless
adverse effects occur.
Q11 (Pharmacodynamics – agonist vs. antagonist): Albuterol is prescribed for a patient with
asthma. The nurse understands that albuterol produces bronchodilation by acting as a:
A. Beta-1 receptor antagonist
B. Beta-2 receptor agonist
C. Alpha-1 receptor agonist
D. Muscarinic receptor antagonist
[CORRECT] B
Pharmacology Review ACTUAL EXAM
2026/2027 | Principles of Pharmacology
Review | Verified Q&A | Pass Guaranteed
- A+ Graded
ART A – MULTIPLE CHOICE (Q1–60)
P
Q1 (Pharmacokinetics – first-pass effect): A patient is prescribed nitroglycerin for acute angina.
The nurse understands that the oral route is avoided for this medication primarily because of
which pharmacokinetic principle?
A. The drug is extensively metabolized by the liver before reaching systemic circulation.
B. The drug is poorly absorbed from the gastrointestinal tract.
C. The drug causes severe gastric irritation when given orally.
D. The drug has a very long half-life and accumulates with oral dosing.
[CORRECT] A
Rationale: The first-pass effect refers to the rapid metabolism of orally administered drugs by
the liver via the portal circulation before they reach systemic circulation, significantly reducing
bioavailability; nitroglycerin has nearly 100% first-pass metabolism, making sublingual or
transdermal routes necessary. Distractor B is incorrect because nitroglycerin is actually well
absorbed from the GI tract but is immediately inactivated by hepatic enzymes. Clinical pearl for
Galen students: Always consider first-pass effect when comparing oral versus parenteral
bioavailability — drugs with high first-pass metabolism require alternative routes to achieve
therapeutic plasma levels.
Q2 (Pharmacokinetics – absorption factors): Which factor would most likely DECREASE the
rate of absorption of an orally administered medication?
A. Taking the medication with a high-fat meal
B. Administering the medication on an empty stomach
C. Using a liquid formulation instead of a tablet
D. Increasing gastric pH with an antacid
[CORRECT] A
Rationale: High-fat meals delay gastric emptying and can reduce the rate of drug absorption by
slowing transit to the small intestine, where most absorption occurs; fats may also bind certain
lipophilic drugs, further reducing availability. Distractor D is incorrect because increasing gastric
pH with antacids can actually enhance absorption of acid-labile drugs by protecting them from
degradation in the stomach. Clinical pearl for Galen students: Always check whether a
medication should be taken with food or on an empty stomach — food can either enhance,
delay, or have no effect on absorption depending on the drug's physicochemical properties.
, 3 (Pharmacokinetics – protein binding): A patient with severe liver cirrhosis has low serum
Q
albumin levels. The nurse anticipates that administration of warfarin, a highly protein-bound
drug, will result in which effect?
A. Decreased therapeutic effect due to increased protein binding
B. Increased risk of bleeding due to higher free drug concentration
C. Prolonged half-life due to decreased hepatic metabolism
D. Decreased drug distribution to target tissues
[CORRECT] B
Rationale: When albumin levels are low, fewer protein-binding sites are available, resulting in a
higher proportion of free (unbound) warfarin circulating in the plasma; free drug is
pharmacologically active and can cause enhanced anticoagulant effects and bleeding risk.
Distractor A is incorrect because decreased albumin actually reduces protein binding, not
increases it. Clinical pearl for Galen students: In patients with hypoalbuminemia (liver disease,
malnutrition, nephrotic syndrome), monitor closely for toxicity with highly protein-bound drugs
like warfarin, furosemide, and phenytoin — free drug levels increase even when total drug levels
appear normal.
Q4 (Pharmacokinetics – blood-brain barrier): The nurse is caring for a patient receiving
morphine for postoperative pain. Which statement best explains why morphine can cross the
blood-brain barrier while many other drugs cannot?
A. Morphine is highly ionized at physiological pH, facilitating passive diffusion.
B. Morphine is lipophilic enough to penetrate the lipid bilayer of the blood-brain barrier.
C. Morphine uses active transport carriers specific to opioid peptides.
D. Morphine is a small molecule that passes through fenestrations in capillary walls.
[CORRECT] B
Rationale: The blood-brain barrier consists of tight junctions between capillary endothelial cells
with a lipid bilayer membrane; lipophilic (lipid-soluble) drugs like morphine can diffuse across
this barrier, whereas hydrophilic (water-soluble) drugs are generally excluded. Distractor A is
incorrect because ionized drugs are typically water-soluble and cannot cross lipid membranes
easily — it is the non-ionized form that crosses. Clinical pearl for Galen students: Lipophilicity is
the key determinant of blood-brain barrier penetration; benzodiazepines, opioids, and general
anesthetics cross easily, while most antibiotics and polar drugs require special transport
mechanisms or inflamed meninges to enter the CNS.
Q5 (Pharmacokinetics – half-life): A drug has a half-life of 6 hours. Approximately how long will
it take for the drug to reach steady-state concentration with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
[CORRECT] D
Rationale: Steady-state concentration is typically reached after approximately 4 to 5 half-lives of
a drug; with a 6-hour half-life, this equates to 24–30 hours (5 × 6 = 30 hours), at which point
drug elimination equals drug administration and plasma levels plateau. Distractor C (24 hours =
4 half-lives) represents near-steady state but not full steady state. Clinical pearl for Galen
students: Use the "5 half-lives rule" to estimate when to expect therapeutic effects or when to
, raw trough levels — for drugs with long half-lives (e.g., digoxin ~36 hours), loading doses may
d
be needed to achieve therapeutic levels quickly.
Q6 (Pharmacokinetics – renal elimination): A patient with chronic kidney disease (CrCl 25
mL/min) is prescribed gentamicin. The nurse knows that renal impairment will primarily affect
which pharmacokinetic parameter?
A. Absorption from the GI tract
B. Volume of distribution
C. Elimination half-life
D. First-pass metabolism
[CORRECT] C
Rationale: The kidneys are the primary route of elimination for aminoglycosides like gentamicin;
impaired renal function decreases glomerular filtration rate (GFR), leading to reduced drug
clearance, accumulation of the drug, and a prolonged elimination half-life. Distractor D is
incorrect because first-pass metabolism is a hepatic process, not renal. Clinical pearl for Galen
students: For renally eliminated drugs (aminoglycosides, vancomycin, digoxin, lithium), always
check creatinine clearance before dosing and adjust intervals or doses accordingly —
therapeutic drug monitoring (TDM) is essential for narrow therapeutic index drugs.
Q7 (Pharmacokinetics – placental transfer): A pregnant patient at 28 weeks gestation asks the
nurse whether the antibiotic she is taking will harm her baby. The nurse's best response is
based on which principle?
A. All drugs cross the placenta and cause teratogenic effects.
B. Only lipid-soluble, non-ionized, low-molecular-weight drugs readily cross the placenta.
C. The placenta is an absolute barrier that prevents all drug transfer to the fetus.
D. Only drugs with a molecular weight greater than 1000 Daltons can cross the placenta.
[CORRECT] B
Rationale: The placenta allows passive diffusion of lipid-soluble, non-ionized,
low-molecular-weight drugs; water-soluble, ionized, and high-molecular-weight drugs (like
heparin) do not readily cross, making this the most accurate explanation for drug transfer risk
assessment. Distractor A is incorrect because not all drugs cross the placenta, and not all that
cross are teratogenic. Clinical pearl for Galen students: When counseling pregnant patients,
remember the PLLR (Pregnancy and Lactation Labeling Rule) — the old A/B/C/D/X categories
were replaced in 2015 with narrative summaries; always consult LactMed for lactation safety
and the PLLR for pregnancy risk information.
Q8 (Pharmacokinetics – CYP450 metabolism): A patient taking warfarin is started on
fluconazole for a fungal infection. The nurse monitors for signs of bleeding because fluconazole
inhibits which enzyme system?
A. Cytochrome P450 3A4
B. Cytochrome P450 2D6
C. Cytochrome P450 2C9
D. Cytochrome P450 1A2
[CORRECT] C
Rationale: Warfarin is primarily metabolized by CYP2C9; fluconazole is a potent inhibitor of
CYP2C9 and CYP3A4, reducing warfarin metabolism and increasing its plasma concentration,
which elevates INR and bleeding risk. Distractor A is incorrect because while CYP3A4 is also
, inhibited by fluconazole, warfarin's S-enantiomer (more potent) is specifically metabolized by
CYP2C9. Clinical pearl for Galen students: Memorize major CYP450 interactions — CYP3A4
(metabolizes ~50% of drugs), CYP2D6 (many antidepressants, beta-blockers), CYP2C9
(warfarin, NSAIDs), and CYP1A2 (theophylline, caffeine); inhibitors increase drug levels,
inducers decrease them.
Q9 (Pharmacokinetics – loading dose): A patient with atrial fibrillation is started on digoxin. The
physician orders a loading dose followed by a maintenance dose. The nurse understands that a
loading dose is given to:
A. Reduce the risk of adverse effects during initial therapy.
B. Achieve therapeutic plasma concentration more rapidly.
C. Compensate for poor oral bioavailability of the drug.
D. Prevent drug accumulation in patients with renal impairment.
[CORRECT] B
Rationale: A loading dose is a higher initial dose administered to rapidly achieve therapeutic
plasma drug concentrations; without it, drugs with long half-lives (like digoxin, ~36 hours) would
take many days to reach steady state at maintenance dosing alone. Distractor A is incorrect
because loading doses actually increase the risk of adverse effects due to higher initial plasma
levels. Clinical pearl for Galen students: Loading doses are commonly used for antibiotics
(vancomycin), antiarrhythmics (amiodarone, digoxin), and anticoagulants — always verify the
patient's renal and hepatic function before administering, as impaired clearance increases
toxicity risk.
Q10 (Pharmacokinetics – steady state): A nurse is teaching a patient about a new
antihypertensive medication with a half-life of 12 hours. The patient asks when they can expect
the full blood pressure-lowering effect. The nurse's best response is:
A. "You should see the full effect within 2 to 3 days."
B. "The full effect will occur after about 5 to 6 days."
C. "The medication works immediately after the first dose."
D. "It may take up to 2 weeks for the full effect."
[CORRECT] B
Rationale: With a 12-hour half-life, steady-state concentration is reached in approximately 4 to 5
half-lives (48–60 hours, or 2 to 2.5 days); however, the full clinical effect of antihypertensives
may take slightly longer as vascular remodeling occurs, making 5 to 6 days a reasonable clinical
estimate. Distractor A underestimates the time needed, and D overestimates it for this half-life.
Clinical pearl for Galen students: When counseling patients on new medications, explain that
steady state is a pharmacokinetic concept (4–5 half-lives), but clinical effects may take
additional time — never discontinue antihypertensives before steady state is reached unless
adverse effects occur.
Q11 (Pharmacodynamics – agonist vs. antagonist): Albuterol is prescribed for a patient with
asthma. The nurse understands that albuterol produces bronchodilation by acting as a:
A. Beta-1 receptor antagonist
B. Beta-2 receptor agonist
C. Alpha-1 receptor agonist
D. Muscarinic receptor antagonist
[CORRECT] B
